September 03, 2025

Vitiligo Depression Risk Varies by Race

Analysis of national health records shows vitiligo is linked to higher depression odds in certain racial and ethnic groups, highlighting variation in mental health burden across populations.

Conexiant

September 03, 2025

Study Maps Delta-Like Protein 3 and SEZ6 Across Tumor Types

Researchers highlight distinct Delta-like protein 3 and seizure-related 6 homolog patterns in neuroendocrine tumors.

Conexiant

September 02, 2025

Misconceptions Regarding Skin Cancer Risk in the United States

Investigators may have uncovered associations between the reported number of sunburns and sociodemographic characteristics as well as the prevalence of protective skin behaviors adopted by U.S. adults...

The ASCO Post

September 02, 2025

Dual Immunotherapy May Improve Progression-Free Survival in Advanced Squamous Cell Carcinoma

A novel immunotherapy combination may improve progression-free survival in patients with advanced cutaneous squamous cell carcinoma compared with avelumab alone, according to findings presented at the...

The ASCO Post

September 02, 2025

Pathology Machine-Learning Models and Diagnosis of Nonmelanoma Skin Cancers in Resource-Limited Settings

Artificial intelligence (AI) models, which were pretrained on vast data sets, outperformed a standard baseline model in identifying nonmelanoma skin cancers from digital images of tissue samples, base...

The ASCO Post

September 02, 2025

Four-Drug Induction Regimen Under Study in Advanced Melanoma With BRAF Mutation

In a phase II trial (EBIN) reported in The Lancet Oncology, Robert et al investigated the survival benefit of adding induction encorafenib/binimetinib to nivolumab/ipilimumab in patients with advanced...

The ASCO Post

September 02, 2025

Role of Mitochondrial Pathways in Melanoma Progression, Treatment Resistance

“This discovery identifies melanoma's excessive reliance on mitochondrial energy as its Achilles’ heel, revealing a therapeutic vulnerability that we can exploit with existing drugs.”

The ASCO Post

September 02, 2025

Four-Year Outcomes Highlight Efficacy of Neoadjuvant Nivolumab and Relatlimab in Advanced Resectable Melanoma

A neoadjuvant and adjuvant regimen of anti–PD-1 therapy with nivolumab and anti–LAG-3 therapy with relatlimab led to a 4-year event-free survival rate of 80% in patients with advanced, resectable mela...

The ASCO Post

September 02, 2025

Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could...

The ASCO Post